Press releases about dementia diagnostic tests often sound revolutionary—announcing breakthroughs in early detection or promising near-perfect accuracy—but deserve immediate scrutiny because they’re written by the companies selling the tests, not by independent researchers assessing whether the tests actually work in real clinical practice. A recent example: a company issued a press release claiming its biomarker test could “identify Alzheimer’s disease years before symptoms,” a statement that conflates detecting a protein abnormality with predicting who will actually develop cognitive decline. The reality is messier. A person can carry Alzheimer’s biomarkers their entire life without ever experiencing dementia, and press releases frequently omit this distinction because it weakens the marketing narrative.
The scrutiny matters because families, caregivers, and patients make real decisions based on what they read. They may pursue expensive tests, seek early drug interventions with uncertain benefits, or experience unnecessary anxiety over asymptomatic findings. Journalists, doctors, and advocacy organizations often amplify these announcements without questioning their framing. A company press release is not peer-reviewed science; it’s a marketing document designed to boost stock prices, secure funding, or establish market dominance. The language is carefully chosen to impress rather than inform.
Table of Contents
- What Makes Press Releases About Dementia Tests Unreliable?
- The Gap Between Detecting a Marker and Predicting Disease
- Conflict of Interest in Company Announcements
- How to Read a Dementia Test Press Release Critically
- Marketing Language That Obscures Limitations
- Regulatory Status and What It Actually Means
- The Absence of Data on What Comes Next
What Makes Press Releases About Dementia Tests Unreliable?
Press releases function as promotional tools, not scientific communication. They highlight positive findings while minimizing limitations, downsides, or contradictions in the broader literature. When a company announces that its test has “90% accuracy,” the press release rarely explains accuracy in what population, tested under what conditions, or whether that accuracy translates to clinical usefulness. Accuracy is also meaningless without context: a test can be 90% accurate at detecting people without disease but miss half of those who will develop it, or vice versa. These nuances get buried or omitted because they complicate the narrative. A real case: In 2021, a diagnostics company released a press statement about a blood biomarker test for Alzheimer’s, presented as a major advance in early detection. Media outlets ran headlines like “Blood Test May Detect Alzheimer’s Years Early.” What the press release de-emphasized was that the test was validated only in research settings with carefully selected participants—mostly cognitively normal older adults with risk factors like family history.
It hadn’t been tested in primary care clinics, hadn’t been evaluated in diverse populations, and hadn’t shown it could change any patient outcomes. A doctor seeing that headline might order the test, but it wasn’t ready for routine use. The structure of a press release is designed to maximize emotional impact. The headline makes the boldest claim. The opening sentences cherry-pick the most impressive statistics. Quotes from company executives come before quotes from independent experts (if any). Limitations and caveats appear near the end, where fewer people read them. This architecture—standard in marketing—distorts scientific truth through selective arrangement.
The Gap Between Detecting a Marker and Predicting Disease
One of the deepest traps in dementia test press releases is the conflation of biomarker presence with disease development. A biomarker is a measurable indicator—like a specific protein in the blood or cerebrospinal fluid, or amyloid and tau visible on a PET scan. A disease is a condition with symptoms and functional decline. These are not the same thing. Many people who show Alzheimer’s biomarkers never develop cognitive symptoms during their lifetime; their brains seem to tolerate the pathology without behavioral consequence. Press releases rarely clarify this distinction because clarity undermines urgency. The limitation is profound: a positive test result tells you nothing about whether or when you’ll develop dementia. A 65-year-old with a positive blood biomarker test might be at higher statistical risk than their biomarker-negative peers, but that risk is still low in absolute terms, and individual variation is enormous.
Some people with biomarkers get dementia at 75; others live to 95 with intact cognition. Press releases avoid discussing this variability because it suggests the test isn’t as predictive as the headline implies. What they typically say instead is that the test offers “earlier detection” or “screening potential”—language that hints at diagnosis without claiming it. An example of how this plays out: A company announced a blood test for phosphorylated tau, a protein linked to Alzheimer’s disease. The press release stated the test could detect Alzheimer’s pathology in cognitively normal people. True. But it didn’t mention that a positive result doesn’t mean you have Alzheimer’s disease, don’t have a timeline, and shouldn’t be told you have an incurable condition. Patients found out the hard way, through media coverage, that they carried biomarkers—and then faced the psychological burden of that knowledge without any approved preventive intervention.
Conflict of Interest in Company Announcements
The company announcing a new dementia test has an obvious financial interest in that test being perceived as essential, accurate, and ready for widespread use. Their scientists conducted the research, designed the validation studies, and selected which results to highlight. Independent scientists were not involved in deciding what to announce or how to frame it. This doesn’t mean the test is fraudulent or useless, but it does mean the announcement is not neutral reporting of science. Consider the incentive structure: A company that announces a narrow, modest limitation to its test will see lower adoption and lower revenue than a company that announces breakthrough potential and minimizes caveats.
The business model rewards optimism, not caution. Venture-backed diagnostic companies have particularly strong incentives to announce big claims early—press releases and media coverage help secure Series A and Series B funding rounds. The science may be real, but the framing is shaped by capital. A practical consequence: A hospital health system might adopt a new test based on a press release, implement it in their memory clinic, and bill patients or insurance for it—all before independent studies confirm its clinical utility. By the time skeptical researchers publish a negative finding in a peer-reviewed journal a year or two later, thousands of patients have had the test, thousands of dollars have been spent, and institutional inertia keeps the test in use anyway.
How to Read a Dementia Test Press Release Critically
The first step is to identify the claim underneath the marketing language. A press release that says a test “identifies” or “detects” or “shows the potential to screen” Alzheimer’s disease is making different claims. Identification and screening are different. Detecting a biomarker is different from diagnosing dementia. Once you identify the actual claim, ask: Was this tested in people with the disease and people without it? What was the population—age, education, race, prior imaging? How many participants? Was an independent research group validating the test, or just the company’s team? Were the results peer-reviewed before announcement? A second red flag: Is the press release comparing the test to the diagnostic standard, or comparing it to no test at all? A test that is 80% accurate sounds impressive until you learn that clinical judgment by an experienced neurologist is 90% accurate and costs less. Press releases often avoid these comparisons because they make the new test look less revolutionary.
If the announcement doesn’t mention false positives and false negatives, it’s hiding important information. A test that catches 95% of future dementia cases sounds great until you learn it also flags 40% of people who will never develop dementia—flooding clinics with false alarms. A practical example: A company announced a cognitive test on a smartphone app, claiming it could detect early cognitive impairment years before standard tests. The press release emphasized the convenience and early warning potential. What it didn’t mention: the test was validated in a research study with educated, tech-savvy participants who took the test repeatedly under controlled conditions. Real-world use—a single test by someone who’s stressed, distracted, or unfamiliar with smartphones—performs very differently. Independent researchers later published findings showing the app’s results didn’t predict cognitive decline better than age alone.
Marketing Language That Obscures Limitations
Certain phrases in press releases serve as red flags because they sound impressive but are scientifically slippery. “Shows promise” and “has potential” are near-meaningless; they could describe early lab work with no clinical application. “May help identify” is vaguer than “identifies.” “Associated with” is weaker than “causes.” “In select populations” or “in research settings” means the test hasn’t been tested where it would actually be used. When a press release uses these hedges in the headline, the company is trying to have it both ways—implying certainty for marketing purposes while maintaining legal deniability through weasel words. A warning: Be skeptical of press releases that announce a test’s availability simultaneously with research results. This suggests the company invested in the marketing rollout before the science was vetted. A company confident in its test can wait for independent replication and peer review.
A company racing to market announces first, publishes second. The goal is to establish public perception and insurance reimbursement codes while the research is still being scrutinized. Another limitation worth noting: Press releases almost never discuss what happens after someone gets a positive result. They don’t mention that there’s no FDA-approved treatment for asymptomatic Alzheimer’s biomarker positivity, no consensus guidelines for managing it, and no evidence that knowing you’re biomarker-positive and cognitively normal changes your life for the better. They announce the test but not the burden it creates. A person who tests positive may face anxiety, discrimination in employment or insurance, or pressure to enroll in clinical trials for experimental drugs. These harms don’t appear in press releases.
Regulatory Status and What It Actually Means
A dementia test can be marketed with different regulatory claims depending on where it was developed. In the United States, a test might be offered as a “laboratory-developed test” (LDT)—available from a single lab without FDA review—or it might be FDA-cleared or FDA-approved. These sound equivalent but aren’t. An FDA-cleared test has undergone some regulatory scrutiny; an LDT can be marketed based on the company’s own validation studies alone.
A press release that doesn’t mention the regulatory pathway is hiding information. If a test is an LDT, that should be stated explicitly, because it means the test wasn’t independently reviewed for accuracy or clinical utility. The press release will often lead with a prestigious affiliation—”researchers from Stanford” or “collaborating with the National Institutes of Health.” These affiliations create credibility but don’t guarantee the company’s claims are accurate. The researchers may have developed the test but aren’t responsible for the marketing. The company can claim association while avoiding responsibility if the press release makes exaggerated statements.
The Absence of Data on What Comes Next
A nearly universal problem with dementia test press releases: they don’t discuss outcomes. They announce a test can detect something, but rarely mention studies tracking whether people who test positive actually develop dementia more often or sooner than those who test negative. This seems like an obvious question to answer before marketing a test, but many press releases predate outcome data. A company can announce “the test identifies Alzheimer’s pathology” and be technically truthful while omitting that half of the people identified never develop symptoms.
One concrete example illustrates the cost of this gap: A blood biomarker test was announced as capable of detecting Alzheimer’s disease “before symptoms.” Patients paid out-of-pocket to take it, received results saying they were biomarker-positive, and often pursued memory clinics, neuropsychological testing, and enrollment in drug trials for asymptomatic people. Years later, follow-up studies showed that many of these biomarker-positive individuals remained cognitively normal. The test worked as designed—it detected the protein—but it wasn’t a disease diagnosis, and the press release had never claimed to predict who would get dementia. Patients made decisions based on the press release’s implication rather than its technical accuracy.
- —
